Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD

Substantial and highly variable placebo response rates represent a major obstacle to antidepressant development in major depressive disorder (MDD). However, whether the likelihood of receiving active treatment or placebo, a proxy of the degree of expectation of improvement, may itself influence clinical trial outcome is unclear. The goal of this work was to examine whether the probability of receiving placebo influences clinical trial outcome antidepressant MDD trials. Medline/Pubmed publication databases were searched for randomized, double-blind, placebo-controlled trials of antidepressants for adults with MDD. 146 manuscripts involving 182 clinical trials were pooled (n = 36,385). Pooled response rates for drug and placebo were 53.8% and 37.3%. A meta-regression (random-effects) established that the probability of receiving placebo, year of publication, and baseline severity were independent predictors of the risk ratio of responding to antidepressants versus placebo. Specifically, a greater probability of receiving placebo, greater baseline severity and an earlier year of publication predicted greater antidepressant-placebo "efficacy separation". Fixed versus flexible dose design, trial duration and population age did not influence clinical trial outcome.

[1]  C. Bell.  DSM-IV: Diagnostic and Statistical Manual of Mental Disorders , 1994 .

[2]  Kathryn A Sexton,et al.  Does elimination of placebo responders in a placebo run‐in increase the treatment effect in randomized clinical trials? A meta‐analytic evaluation , 2004, Depression and anxiety.

[3]  A. Rush,et al.  The Montgomery Äsberg and the Hamilton ratings of depression: A comparison of measures , 2006, European Neuropsychopharmacology.

[4]  M. Trivedi,et al.  Does a Placebo Run-In or a Placebo Treatment Cell Affect the Efficacy of Antidepressant Medications? , 1994, Neuropsychopharmacology.

[5]  E. Robins,et al.  Research diagnostic criteria: rationale and reliability. , 1978, Archives of general psychiatry.

[6]  Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative Research Program. , 1991 .

[7]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[8]  Arif Khan,et al.  Relative sensitivity of the Montgomery–Åsberg depression rating scale, the Hamilton depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials: a replication analysis , 2004, International clinical psychopharmacology.

[9]  David A. Schoenfeld,et al.  The Problem of the Placebo Response in Clinical Trials for Psychiatric Disorders: Culprits, Possible Remedies, and a Novel Study Design Approach , 2003, Psychotherapy and Psychosomatics.

[10]  Dan J Stein,et al.  Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. , 2006, The Journal of clinical psychiatry.

[11]  S. Khana,et al.  Relative sensitivity of the Montgomery-Asberg Depression Rating Scale , the Hamilton Depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials , 2009 .

[12]  Russell L. Kolts,et al.  Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. , 2004, The American journal of psychiatry.

[13]  J. Feighner,et al.  Diagnostic criteria for use in psychiatric research. , 1972, Archives of general psychiatry.

[14]  D DeBrota,et al.  The responsiveness of the Hamilton Depression Rating Scale. , 2000, Journal of psychiatric research.

[15]  R. Sysko,et al.  Placebo response in studies of major depression: variable, substantial, and growing. , 2002, JAMA.

[16]  Robyn M Leventhal,et al.  Severity of Depression and Response to Antidepressants and Placebo: An Analysis of the Food and Drug Administration Database , 2002, Journal of clinical psychopharmacology.

[17]  Russell L. Kolts,et al.  Relationship Between Depression Severity Entry Criteria and Antidepressant Clinical Trial Outcomes , 2007, Biological Psychiatry.

[18]  E. Giller,et al.  Frequency of Positive Studies Among Fixed and Flexible Dose Antidepressant Clinical Trials: An Analysis of the Food and Drug Administraton Summary Basis of Approval Reports , 2003, Neuropsychopharmacology.

[19]  M. Shea,et al.  Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative Research Program. , 1991, The American journal of psychiatry.

[20]  J. Wernicke,et al.  Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: The absence of an effect related to agitation and suicidal behavior , 1997, Depression and anxiety.

[21]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[22]  G. Tollefson,et al.  The Double-Blind Variable Placebo Lead-in Period: Results From Two Antidepressant Clinical Trials , 2001, Journal of clinical psychopharmacology.